Table 2 Relationship between F. nucleatum status and clinical, biological and pathological characteristics of the 151 patients of the merged cohort.

From: Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients

Ā 

Patients (%)

Number of patients (%)

p-valuea

F. nucleatum negative

F. nucleatum positive

Total

151 (100)

27 (17.9)

124 (82.1)

Ā 

Age

<ā€‰56

45 (29.8)

13 (48.1)

32 (25.8)

0.021*

ā‰„ā€‰56

106 (70.2)

14 (51.9)

92 (74.2)

Ā 

Sex

Female

58 (38.4)

7 (25.9)

51 (41.1)

0.14 (NS)

Male

93 (61.6)

20 (74.1)

73 (58.9)

Ā 

Alcoholb

No

79 (61.2)

8 (40)

71 (65.1)

0.034*

Yes

50 (38.8)

12 (60)

38 (34.9)

Ā 

Tobaccoc

No

62 (44.9)

7 (28)

55 (48.7)

0.060 (NS)

Yes

76 (55.1)

18 (72)

58 (51.3)

Ā 

Alcohol and tobaccob

No

84 (65.1)

9 (45.0)

75 (68.8)

0.040*

Yes

45 (34.9)

11 (55.0)

34 (31.2)

Ā 

pT

1

21 (13.9)

3 (11.1)

18 (14.5)

0.30 (NS)

2

38 (25.2)

7 (25.9)

31 (25.0)

Ā 

3

58 (38.4)

14 (51.9)

44 (35.5)

Ā 

4

34 (22.5)

3 (11.1)

31 (25.0)

Ā 

pN

0

81 (53.6)

9 (33.3)

72 (58.1)

0.0016**

1

15 (9.9)

0 (0)

15 (12.1)

Ā 

2

23 (15.2)

6 (22.2)

17 (13.7)

Ā 

3

32 (21.2)

12 (44.4)

20 (16.1)

Ā 

Differentiationd

Verrucous

4 (2.8)

0 (0)

4 (3.4)

0.062 (NS)

Grade I

106 (73.1)

20 (76.9)

87 (73.1)

Ā 

Grade II

27 (18.6)

3 (11.5)

24 (20.2)

Ā 

Grade III

8 (5.5)

4 (15.4)

4 (3.4)

Ā 

Grade IV

0 (0)

0 (0)

0 (0)

Ā 

Marginse

Negative or close

122 (83.6)

20 (76.9)

102 (85.0)

0.47 (NS)

Positive

24 (16.4)

6 (23.1)

18 (15.0)

Ā 

HPV

Negative

147 (97.4)

25 (92.6)

122 (98.4)

0.15 (NS)

Positive

4 (2.6)

2 (7.4)

2 (1.6)

Ā 

UICC stage

Stage I

20 (13.2)

2 (7.4)

18 (14.5)

0.32 (NS)

Stage II

37 (24.5)

4 (14.8)

33 (26.6)

Ā 

Stage III

30 (19.9)

6 (22.2)

24 (19.4)

Ā 

Stage IV

64 (42.4)

15 (55.6)

49 (39.5)

Ā 

TP53 mutational status

Wild-type

55 (36.4)

8 (29.6)

47 (37.9)

0.42 (NS)

Mutated

96 (63.6)

19 (70.4)

77 (62.1)

Ā 

PIK3CA mutational status

Wild-type

133 (88.1)

23 (85.2)

110 (88.7)

0.85 (NS)

Mutated

18 (11.9)

4 (14.8)

14 (11.3)

Ā 

Relapse

No

93 (61.6)

13 (48.2)

80 (64.5)

0.11 (NS)

Yes

58 (38.4)

14 (51.8)

44 (35.5)

Ā 

Locoregional relapse

38 (65.5)

8 (53.3)

31 (70.5)

0.041*

Distant metastasis

11 (19.0)

6 (40.0)

5 (11.4)

Ā 

Both

9 (15.5)

1 (6.7)

8 (18.2)

Ā 
  1. HPV human papilloma virus, UICC Union for international cancer control, NS Not significant.
  2. *pā€‰<ā€‰0.05.
  3. **pā€‰<ā€‰0.01.
  4. ***pā€‰<ā€‰0.001.
  5. aChi-square test, Chi-square test with Yatesā€™ correction or Fisher test if appropriate.
  6. bInformation available for 129 patients.
  7. cInformation available for 138 patients.
  8. dInformation available for 145 patients.
  9. eInformation available for 146 patients.
Back to article page